List of proteins involved in transport and co-immunoprecipitated with IL13Rα2

RGD mAbs blocking effects require the presence of α2 integrin

List of antibodies used in the different applications

Breast cancer and melanoma cell lines do not express CDH17

RGD-specific mAbs inhibit activation of β1 integrin, cell adhesion and proliferation only in CDH17-positive colon cancer cells.

Supplementary Table S5. Markers CAFs expressed preferentially in tumoral stroma of colorectal cancer using inmunohistochemistry of Human Protein Atlas

Supplementary Table S4. Genomatix Analysis of the predicted important biological functions

Functional characterization of CDH17 RGD-specific antibodies

RGD mAbs do not affect tubule formation or vascular permeability

Supplementary Methodology Legends to supplementary figures

RGD-specific mAbs inhibit activation of β1 integrin, cell adhesion, proliferation and invasion of melanoma and breast cancer cells

Supplementary Table S3. List of proteins differentially-expressed in the whole cellular extract and conditioned medium of CAFs with a fold-change >1.5

List of proteins involved in transport and co-immunoprecipitated with FAM120A

Supplementary Table 1 from A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma

Supplementary Table S1A: Clinical characteristics of patients studied for CAFs proteomic analysis. Supplementary Table S1B: Clinical data of colon cancer samples used for validation qPCR analysis. Supplementary Table S1C: Clinical data of colon cancer samples used for validation by immunohistochemistry

(271 KB) - Supplementary Figure S1. Expression of IL4R and IL13R1 in KM12 cells. Supplementary Figure S2. IL-13 quantification in conditioned medium of KM12 cells. Supplementary Figure S3. IL13R1 is not involved in cell migration and invasion in response to IL-13. Supplementary Figure S4. Overexpression of IL13R2 increases cell migration and invasion in response to IL-13.

Supplementary Table S2. Global list of proteins identified and quantified in the whole cellular extract and conditioned medium of CAFs

Supplementary figures S1-7. Figure S1. Characterization of fibroblasts isolated from patients with colon cancer. Figure S2. Proteins identified and quantified in both replicates of iTRAQ. Figure S3. Major signaling pathways affected by fibroblast activation. Figure S4 Expression of stromal biomarkers in tissues of colorectal cancer patients using HPA. Figure S5. Prognostic value of individual CAFs markers for overall survival according to GSE17538 dataset. Figure S6. Prognostic value of individual CAFs markers for disease-free survival according to GSE17538 in patients at stages I-III. Figure S7. Nuclear staining of LOXL2 in the stroma of human colon cancer

Characterization of anti-CDH17 RGD mAbs

(116 KB) - Additional methods information